tiprankstipranks
Trending News
More News >
Wuxi Biologics (Cayman) Inc. (WXIBF)
OTHER OTC:WXIBF
US Market
Advertisement

Wuxi Biologics (Cayman) (WXIBF) Stock Forecast & Price Target

Compare
151 Followers
See the Price Targets and Ratings of:

WXIBF Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Wuxi
Biologics (Cayman)
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

WXIBF Stock 12 Month Forecast

Average Price Target

$5.48
▲(35.64% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Wuxi Biologics (Cayman) in the last 3 months. The average price target is $5.48 with a high forecast of $6.42 and a low forecast of $4.30. The average price target represents a 35.64% change from the last price of $4.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.4187,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.300529,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.6,4.7399,4.8797999999999995,5.0197,5.1596,5.2995,5.4394,5.5793,5.7192,5.8591,5.9990000000000006,6.1389000000000005,6.2788,{"y":6.4187,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.6,4.667692307692308,4.735384615384615,4.803076923076923,4.8707692307692305,4.938461538461539,5.006153846153846,5.073846153846154,5.141538461538461,5.2092307692307696,5.276923076923077,5.344615384615385,5.412307692307692,{"y":5.48,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.6,4.576963769230769,4.553927538461538,4.530891307692308,4.507855076923077,4.484818846153846,4.461782615384616,4.438746384615384,4.415710153846153,4.392673923076923,4.369637692307692,4.346601461538461,4.323565230769231,{"y":4.300529,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6.42Average Price Target$5.48Lowest Price Target$4.30
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on WXIBF
Morgan Stanley
Morgan Stanley
$4.49$5.78
Buy
42.99%
Upside
Reiterated
11/20/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on WXIBF
Goldman Sachs
Goldman Sachs
$3.76$4.3
Hold
6.45%
Upside
Reiterated
10/17/25
Goldman Sachs Keeps Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)
Jefferies Analyst forecast on WXIBF
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$6.42
Buy
58.88%
Upside
Reiterated
10/08/25
HSBC
$4.81$5.78
Buy
42.99%
Upside
Reiterated
09/26/25
HSBC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)HSBC analyst Linda Shu raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$45.00 (from HK$37.50) while maintaining a Buy rating.
Macquarie Analyst forecast on WXIBF
Macquarie
Macquarie
$5.13
Buy
27.10%
Upside
Reiterated
09/08/25
Macquarie Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)Macquarie analyst Tony Ren reiterated an Outperform rating and HK$40.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).
UBS
$5.43$6.02
Buy
49.03%
Upside
Reiterated
09/03/25
UBS Reaffirms Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF)we revise up our Wuxi Apptec/Wuxi Bio long-term operation estimates with lower WACC, raising our DCF-based price targets from HK$119.80 /HK$42.30 to HK$136.10/HK$46.90. ... We maintain our Buy ratings.
Guotai Haitong Analyst forecast on WXIBF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$6.19
Buy
53.10%
Upside
Reiterated
08/31/25
DBS
$3$4.62
Hold
14.39%
Upside
Reiterated
08/26/25
DBS Sticks to Their Hold Rating for Wuxi Biologics (Cayman) (WXIBF)
CCB Intl. Analyst forecast on WXIBF
Unknown Analyst
CCB Intl.
Not Ranked
CCB Intl.
$5.01
Buy
23.93%
Upside
Reiterated
08/26/25
CLSA
$4.47$5.47
Buy
35.36%
Upside
Reiterated
08/25/25
Guotai Haitong Analyst forecast on WXIBF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$6.19
Buy
53.10%
Upside
Reiterated
08/23/25
CMB International Securities Analyst forecast on WXIBF
CMB International Securities
CMB International Securities
$4.57
Buy
13.12%
Upside
Reiterated
08/21/25
J.P. Morgan Analyst forecast on WXIBF
J.P. Morgan
J.P. Morgan
$4.62$4.75
Buy
17.57%
Upside
Reiterated
08/21/25
J.P. Morgan Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)JPMorgan analyst Yang Huang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$37.00 (from HK$36.00) while maintaining a Overweight rating.
Citi
$4.49$5.13
Buy
27.10%
Upside
Reiterated
08/21/25
Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Citi
BOCOM International Holdings Company Analyst forecast on WXIBF
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$4.36
Hold
8.04%
Upside
Reiterated
08/21/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on WXIBF
Morgan Stanley
Morgan Stanley
$4.49$5.78
Buy
42.99%
Upside
Reiterated
11/20/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on WXIBF
Goldman Sachs
Goldman Sachs
$3.76$4.3
Hold
6.45%
Upside
Reiterated
10/17/25
Goldman Sachs Keeps Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)
Jefferies Analyst forecast on WXIBF
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$6.42
Buy
58.88%
Upside
Reiterated
10/08/25
HSBC
$4.81$5.78
Buy
42.99%
Upside
Reiterated
09/26/25
HSBC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)HSBC analyst Linda Shu raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$45.00 (from HK$37.50) while maintaining a Buy rating.
Macquarie Analyst forecast on WXIBF
Macquarie
Macquarie
$5.13
Buy
27.10%
Upside
Reiterated
09/08/25
Macquarie Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)Macquarie analyst Tony Ren reiterated an Outperform rating and HK$40.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).
UBS
$5.43$6.02
Buy
49.03%
Upside
Reiterated
09/03/25
UBS Reaffirms Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF)we revise up our Wuxi Apptec/Wuxi Bio long-term operation estimates with lower WACC, raising our DCF-based price targets from HK$119.80 /HK$42.30 to HK$136.10/HK$46.90. ... We maintain our Buy ratings.
Guotai Haitong Analyst forecast on WXIBF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$6.19
Buy
53.10%
Upside
Reiterated
08/31/25
DBS
$3$4.62
Hold
14.39%
Upside
Reiterated
08/26/25
DBS Sticks to Their Hold Rating for Wuxi Biologics (Cayman) (WXIBF)
CCB Intl. Analyst forecast on WXIBF
Unknown Analyst
CCB Intl.
Not Ranked
CCB Intl.
$5.01
Buy
23.93%
Upside
Reiterated
08/26/25
CLSA
$4.47$5.47
Buy
35.36%
Upside
Reiterated
08/25/25
Guotai Haitong Analyst forecast on WXIBF
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$6.19
Buy
53.10%
Upside
Reiterated
08/23/25
CMB International Securities Analyst forecast on WXIBF
CMB International Securities
CMB International Securities
$4.57
Buy
13.12%
Upside
Reiterated
08/21/25
J.P. Morgan Analyst forecast on WXIBF
J.P. Morgan
J.P. Morgan
$4.62$4.75
Buy
17.57%
Upside
Reiterated
08/21/25
J.P. Morgan Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)JPMorgan analyst Yang Huang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$37.00 (from HK$36.00) while maintaining a Overweight rating.
Citi
$4.49$5.13
Buy
27.10%
Upside
Reiterated
08/21/25
Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Citi
BOCOM International Holdings Company Analyst forecast on WXIBF
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$4.36
Hold
8.04%
Upside
Reiterated
08/21/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wuxi Biologics (Cayman)

1 Month
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+11.53%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +11.53% per trade.
3 Months
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+10.80%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +10.80% per trade.
1 Year
Yang HuangJ.P. Morgan
Success Rate
4/4 ratings generated profit
100%
Average Return
+41.77%
reiterated a buy rating 3 months ago
Copying Yang Huang's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +41.77% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
100%
Average Return
+41.77%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WXIBF Analyst Recommendation Trends

Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
12
16
17
16
6
Buy
0
0
0
0
0
Hold
3
5
5
5
2
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
15
22
23
22
8
In the current month, WXIBF has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. WXIBF average Analyst price target in the past 3 months is 5.48.
Each month's total comprises the sum of three months' worth of ratings.

WXIBF Financial Forecast

WXIBF Earnings Forecast

Next quarter’s earnings estimate for WXIBF is $0.08 with a range of $0.08 to $0.08. The previous quarter’s EPS was $0.08. WXIBF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year WXIBF has Performed in-line its overall industry.
Next quarter’s earnings estimate for WXIBF is $0.08 with a range of $0.08 to $0.08. The previous quarter’s EPS was $0.08. WXIBF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year WXIBF has Performed in-line its overall industry.

WXIBF Sales Forecast

Next quarter’s sales forecast for WXIBF is $1.65B with a range of $1.65B to $1.65B. The previous quarter’s sales results were $1.37B. WXIBF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year WXIBF has Performed in-line its overall industry.
Next quarter’s sales forecast for WXIBF is $1.65B with a range of $1.65B to $1.65B. The previous quarter’s sales results were $1.37B. WXIBF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year WXIBF has Performed in-line its overall industry.

WXIBF Stock Forecast FAQ

What is WXIBF’s average 12-month price target, according to analysts?
Based on analyst ratings, Wuxi Biologics (Cayman) Inc.’s 12-month average price target is 5.48.
    What is WXIBF’s upside potential, based on the analysts’ average price target?
    Wuxi Biologics (Cayman) Inc. has 35.64% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is WXIBF a Buy, Sell or Hold?
          Wuxi Biologics (Cayman) Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Wuxi Biologics (Cayman) Inc.’s price target?
            The average price target for Wuxi Biologics (Cayman) Inc. is 5.48. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $6.42 ,the lowest forecast is $4.30. The average price target represents 35.64% Increase from the current price of $4.04.
              What do analysts say about Wuxi Biologics (Cayman) Inc.?
              Wuxi Biologics (Cayman) Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of WXIBF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis